clinical trial · NCT04365868
Study Evaluating the Efficacy and Safety of Belapectin for the Prevention of Esophageal Varices in NASH Cirrhosis
Prevention of Esophageal VaricesNASH - Nonalcoholic SteatohepatitisCirrhosisbelapectinPlacebo
brief summary
This seamless, adaptive, two-stage, Phase 2b/3, randomized, double-blind, multicenter, parallel-groups, placebo-controlled study will assess the efficacy, safety, and tolerability of belapectin compared with placebo in patients with nonalcoholic steatohepatitis (NASH) cirrhosis and clinical signs of portal hypertension but without esophageal varices at baseline.
started
Jun 25, 2020
primary completion
Mar 11, 2025
completion
Apr 10, 2025
last updated
Feb 20, 2026
official title
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol